At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 179 enrolled
Drug / intervention
Rivaroxaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Type-2 Diabetic Patients With Very High Cardiovascular Risk and Subclinical Inflammation
In Brief
A Phase 3 clinical trial evaluating Rivaroxaban and Aspirin for Type 2 Diabetic Patients. Completed, enrolled 179 participants across 5 sites.
Detailed Summary
Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to low dose aspirin in type 2 diabetic patients. Especially patients with cardiovascular disease and subclinical inflammation are in the focus of interest.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetic Patients
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartApr 2015
Primary CompletionDec 2018
Study CompletionApr 2020
TodayJul 2026
First PostedJun 16, 2014
Enrollment StartApr 1, 2015
Primary CompletionDec 12, 2018
Study CompletionApr 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.0 years ago
Interventions
Rivaroxabandrug
Aspirindrug